Antiplatelets NCLEX — Aspirin Clopidogrel Ticagrelor P2Y12 Inhibitors Nursing | NurseNest

Antiplatelets NCLEX — Aspirin Clopidogrel Ticagrelor P2Y12 Inhibitors Nursing | NurseNest

Key Concepts

Drug Overview

Antiplatelet Classes: | Drug | Class | Mechanism | |---|---|---| | Aspirin | COX-1 inhibitor | Irreversible platelet thromboxane A2 block | | Clopidogrel (Plavix) | P2Y12 ADP receptor antagonist | Irreversible block after CYP2C19 activation | | Ticagrelor (Brilinta) | P2Y12 ADP receptor antagonist | Direct (no activation needed); reversible | | Prasugrel (Effient) | P2Y12 ADP receptor antagonist | Requires activation; most potent | | Dipyridamole | PDE inhibitor | Blocks platelet aggregation | | Abciximab (ReoPro) | GP IIb/IIIa inhibitor | IV; PCI only | DAPT (Dual Antiplatelet Therapy): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - Mandatory after coronary stent placement - Duration: 12 months minimum after drug-eluting stent - Major risk: bleeding; benefit: stent thrombosis prevention On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit. If the stem names a license or role, reread that line; scope errors are classic trap answers even when the clinical topic is familiar. Run a 60-second scan: breathing work and oxygenation, perfusion and end organs, neuro baseline, likely infection sources, and...

Mechanisms & Clinical Use

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Signs and Symptoms

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Red Flags / Danger Signs

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Nursing Considerations

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Clinical Pearls & Exam Tips

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Client Education

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Your exam focus

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Next steps

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Unlock full lesson + practice questions

8 more sections with scenarios, priorities, and review drills.

Start free trial Sign in

Retention & exam readiness

Clinical pearls, traps, safety priorities, quick recall, and related concepts live here so the main lesson stays calm and uninterrupted.

Review after learning, not during it.

Topic overview

NCLEX antiplatelet pharmacology: aspirin mechanism, clopidogrel (Plavix) activation, ticagrelor, DAPT after stent, GI bleeding precautions, nursing priorities.

Clinical reasoning

For Antiplatelet Agents, connect the assessment cue to the immediate risk before selecting an action for NP. Start with stability, ABCs, neurologic change, medication risk, infection risk, and scope of practice. Then decide whether the safest next step is assess, intervene, escalate, teach, or evaluate response.

Patient safety implications

A missed priority in Antiplatelet Agents can delay recognition of deterioration or allow preventable harm to continue. Protect the client first by verifying abnormal cues, using ordered precautions, escalating unstable findings, and reassessing after intervention.

Example application

Next study step

Continue Your Learning

Finish the lesson first, then choose a focused activity to apply what you just reviewed.

Practice QuestionsApply this topic with board-style rationales.Open activity

Continue studying

Review Flashcards Practice Related QuestionsContinue Weak Area RecoveryRecommended Next Lesson Take A Readiness Quiz

Practice this topic

Flashcards (same topic)Topic practice tests← All lessons

Sign in to save progress on this lesson.

Drug Overview: Antiplatelet Classes: | Drug | Class | Mechanism | |---|---|---| | Aspirin | COX-1 inhibitor | Irreversible platelet thromboxane A2 block | | Clopidogrel (Plavix) | P2Y12 ADP receptor antagonist | Irreversible block after CYP2C19 activation | | Ticagrelor (Brilinta) | P2Y12 ADP receptor antagonist | Direct (no activation needed); reversible | | Prasugrel (Effient) | P2Y12 ADP receptor antagonist | Requires activation; most potent | | Dipyridamole | PDE inhibitor | Blocks platelet aggregation | | Abciximab (ReoPro) | GP IIb/IIIa inhibitor | IV; PCI only | DAPT (Dual Antiplatelet Therapy): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - Mandatory after coronary stent placement - Duration: 12 months minimum after drug-eluting stent - Major risk: bleeding; benefit: stent thrombosis prevention On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Drug Overview: Antiplatelet Classes: | Drug | Class | Mechanism | |---|---|---| | Aspirin | COX-1 inhibitor | Irreversible platelet thromboxane A2 block | | Clopidogrel (Plavix) | P2Y12 ADP receptor antagonist | Irreversible block after CYP2C19 activation | | Ticagrelor (Brilinta) | P2Y12 ADP receptor antagonist | Direct (no activation needed); reversible | | Prasugrel (Effient) | P2Y12 ADP receptor antagonist | Requires activation; most potent | | Dipyridamole | PDE inhibitor | Blocks platelet aggregation | | Abciximab (ReoPro) | GP IIb/IIIa inhibitor | IV; PCI only | DAPT (Dual Antiplatelet Therapy): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - Mandatory after coronary stent placement - Duration: 12 months minimum after drug-eluting stent - Major risk: bleeding; benefit: stent thrombosis prevention On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Drug Overview: Antiplatelet Classes: | Drug | Class | Mechanism | |---|---|---| | Aspirin | COX-1 inhibitor | Irreversible platelet thromboxane A2 block | | Clopidogrel (Plavix) | P2Y12 ADP receptor antagonist | Irreversible block after CYP2C19 activation | | Ticagrelor (Brilinta) | P2Y12 ADP receptor antagonist | Direct (no activation needed); reversible | | Prasugrel (Effient) | P2Y12 ADP receptor antagonist | Requires activation; most potent | | Dipyridamole | PDE inhibitor | Blocks platelet aggregation | | Abciximab (ReoPro) | GP IIb/IIIa inhibitor | IV; PCI only | DAPT (Dual Antiplatelet Therapy): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - Mandatory after coronary stent placement - Duration: 12 months minimum after drug-eluting stent - Major risk: bleeding; benefit: stent thrombosis prevention On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Drug Overview: Antiplatelet Classes: | Drug | Class | Mechanism | |---|---|---| | Aspirin | COX-1 inhibitor | Irreversible platelet thromboxane A2 block | | Clopidogrel (Plavix) | P2Y12 ADP receptor antagonist | Irreversible block after CYP2C19 activation | | Ticagrelor (Brilinta) | P2Y12 ADP receptor antagonist | Direct (no activation needed); reversible | | Prasugrel (Effient) | P2Y12 ADP receptor antagonist | Requires activation; most potent | | Dipyridamole | PDE inhibitor | Blocks platelet aggregation | | Abciximab (ReoPro) | GP IIb/IIIa inhibitor | IV; PCI only | DAPT (Dual Antiplatelet Therapy): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) - Mandatory after coronary stent placement - Duration: 12 months minimum after drug-eluting stent - Major risk: bleeding; benefit: stent thrombosis prevention On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.